Roche divides and sets out to conquer
Wednesday, 07 February, 2007
Pharma and diagnostics giant Roche has announced a restructure of its global R&D activities, dividing its operating model into specific therapeutic fields.
In a statement, the company said that under the new model each of five disease biology areas (DBA) will be responsible for a range of activities, from R&D to strategic marketing, managing compounds from drug discovery through to medical proof of concept and through to the market
Headquarters for each of the areas will be co-located in the Swiss company's base in Basel, as well as Nutley in New Jersey and Palo Alto in California.
The five DBAs are:
Oncology, based in Nutley, New Jersey
Virology, based in Palo Alto, California
Inflammation, based in Palo Alto, California
Metabolism, based in Basel
Central nervous system, based in Basel
"Roche's R&D efforts continue to focus on clinically differentiated medicines," the company said. "This new model is designed to ensure that Roche's steadily expanding R&D operation is suitably equipped to meet increasingly complex requirements.
"By simplifying and accelerating the multiple decision-making processes involved, the model will be more efficient and effective in translating research activity in each therapeutic area into clinically differentiated medicines. It will also enable the group's growing number of development projects to be integrated more quickly."
Roche said it expects to further increase R&D staff numbers this year as well as its R&D budget, which is currently approximately six billion Swiss francs (A$6.5 bn).
In addition to Basel, Nutley and Palo Alto, therapeutic protein research will be intensified at its Penzberg site in Germany, as will R&D activities in Shanghai.
The company said its current pharmaceutical pipeline includes 61 new molecular entities and 54 additional indications in development addressing major unmet medical needs. The big movers in the near future are expected to come from the areas of oncology, autoimmune diseases and metabolic disorders.
Oxytocin analogue treats chronic abdominal pain
Researchers have developed a new class of oral painkillers to suppress chronic abdominal pain,...
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
